Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. Coiffier B, et al. Among authors: casasnovas o. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27010483 Free article. Clinical Trial.
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Moreau P, Fleury J, Brice P, Colombat P, Bouabdallah R, Lioure B, Voillat L, Casasnovas O, François S, Sadoun A, Lamy T, Lotz JP, Munck JN, Divine M, Fermé C, Pény AM, Fruchart C, Oriol P, Ojeda M, Reman O, Milpied N, Gisselbrecht C, Legros M, Harousseau JL. Moreau P, et al. Among authors: casasnovas o. Bone Marrow Transplant. 1998 Apr;21(8):787-93. doi: 10.1038/sj.bmt.1701174. Bone Marrow Transplant. 1998. PMID: 9603402
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte. Bienvenu J, et al. Among authors: casasnovas o. Hematol J. 2001;2(6):378-84. doi: 10.1038/sj.thj.6200133. Hematol J. 2001. PMID: 11920277 Clinical Trial.
Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study.
Dumontet C, Mounier N, Munck JN, Bosly A, Morschauser F, Simon D, Marit G, Casasnovas O, Reman O, Molina T, Reyes F, Coiffier B. Dumontet C, et al. Among authors: casasnovas o. Br J Haematol. 2002 Jul;118(1):210-7. doi: 10.1046/j.1365-2141.2002.03565.x. Br J Haematol. 2002. PMID: 12100150 Free article. Clinical Trial.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Coiffier B, et al. Among authors: casasnovas o. J Clin Oncol. 2003 Dec 1;21(23):4402-6. doi: 10.1200/JCO.2003.04.115. Epub 2003 Oct 27. J Clin Oncol. 2003. PMID: 14581437 Clinical Trial.
A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Fermé C, Brice P, Michallet AS, Lederlin P, Diviné M, Casasnovas O, Devidas A, Anglaret B, Cazals-Hatem D, Mounier N; Groupe d'Etudes des Lymphomes de L'adulte. Fermé C, et al. Among authors: casasnovas o. Leuk Lymphoma. 2007 Apr;48(4):691-8. doi: 10.1080/10428190601175369. Leuk Lymphoma. 2007. PMID: 17454626 Clinical Trial.
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH; Groupe d'étude des lymphomes de l'adulte. Plonquet A, et al. Among authors: casasnovas o. Ann Oncol. 2007 Jul;18(7):1209-15. doi: 10.1093/annonc/mdm110. Epub 2007 May 12. Ann Oncol. 2007. PMID: 17496307 Free article. Clinical Trial.
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Ribrag V, et al. Among authors: casasnovas o. Blood. 2009 Apr 2;113(14):3307-13. doi: 10.1182/blood-2008-03-148874. Epub 2008 Sep 3. Blood. 2009. PMID: 18768784 Free article.
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Morschhauser F, et al. Among authors: casasnovas o. J Clin Oncol. 2008 Dec 20;26(36):5980-7. doi: 10.1200/JCO.2007.15.5887. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018090 Clinical Trial.
180 results